Stablepharma Revenue and Competitors

'Every 20 seconds a child dies from a vaccine preventable disease' (Bill & Melinda Gates Foundation) Stablepharma have invented and patented a solution to eradicate the ‘cold chain' (refrigeration) process and which will help improve the success and reach of vaccination programmes. The Problem: Vaccines are perishable requiring constant, precise refrigeration from the manufacturer to the patient, be it in a hospital or a remote clinic in Africa. The WHO estimate that c 50% of all vaccines manufactured are wasted in spite of c $400m p.a. spent on the global Cold Chain. The Solution: StablevaX is a patented invention which enables vaccines to be transported & stored for many years without refrigeration whilst complying with current protocols set by the WHO. It's an important breakthrough that can save many lives. The StablevaX products comprise approved vaccines which are dried from a solution of stabilising sugar into the pores of a special sponge stored in a normal vaccination syringe. They are pre-dosed and safe, to use you just add water. StablevaX vaccines can be manufactured at approximately the same price as current products. Stablepharma has completed the R&D phase of its journey. The Proof of Concept milestone has been independently verified in a WHO accredited Laboratory (National Institute of Biological Standards and Controls). With clear commercial opportunities, Stablepharma now plan to enter the c. $50bn human vaccine market to exploit this truly disruptive invention. A pilot scale production plant has been designed, with expert staff & premises secured in Switzerland. Stablepharma is now seeking investment to take this ground-breaking invention to the rest of the world, to start eradicating vaccine wastage and save lives. Join us in changing the future of healthcare!